{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007957","form_type":"8-K","ticker":null,"cik":"0001711933","company_name":"Akoya Biosciences, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.699026+00:00","generated_at":"2026-06-02T02:28:41.487883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akoya Q1 revenue falls 14% to $18.4M; cuts FY2024 revenue guidance to $104-$112M","bullets":["Revenue $18.4M, down 14% YoY; GAAP operating loss $21.6M (non-GAAP $15.2M).","GAAP gross margin 46% (57% non-GAAP adjusted) from legacy instrument write-off.","Installed base up 22% to 1,213; 1,307 publications +52% YoY.","Cash $61.6M; reaffirms target of operating cash flow breakeven by year-end 2024.","Cites capex pressure, deferred pharma lab revenue, and reagent fulfillment delays."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007957","json":"https://secwatch.observer/filing/0001558370-24-007957.json","markdown":"https://secwatch.observer/filing/0001558370-24-007957.md","text":"https://secwatch.observer/filing/0001558370-24-007957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/0001558370-24-007957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/akya-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:28:41.487883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eba51f7ae48159ce30d04d0e13f8eae3c1f80f49","claim":"Akoya Biosciences, Inc. reported the first quarter ending March 31, 2024 results: revenue $18.4 million. Guidance lowered.","evidence_excerpt":"(Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. ​ Business Highlights ​ ● Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase. ● Akoya announced the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/0001558370-24-007957-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2024"},{"label":"Revenue","value":"$18.4 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}